We believe our drug Prolanta™ has the opportunity to treatment a wide range of human cancers. There is substantial scientific evidence that human prolactin is associated with the growth of many cancers as well as the development of resistance to common chemotherapies. See Human Prolactin and Cancer and Human Prolactin and Chemo. As as result, we believe Prolanta™ will be effective against many cancers both as a stand-alone therapy as well as part of combination therapy.
Prolanta™ is a recombinant analogue to human prolactin and acts as an antagonist to the prolactin receptor. The drug is designed to bind to the prolactin receptor, interfering with the binding of human prolactin, but not stimulating the intracellular pathways that lead to cell proliferation and drug resistance. See Prolanta™ Structure.
Ovarian Cancer. Our initial focus is ovarian cancer, and we have an FDA-cleared Investigational New Drug (IND) application to commence a Phase I human trial. Based on our preclinical evidence of expected efficacy, the FDA has also granted Prolanta™ Orphan Drug status for the treatment of ovarian cancer. Our collaborators at The University Texas MD Anderson Cancer Center developed the efficacy data in ovarian cancer, which was published in Cell Reports (see Scientific Publications). These researchers demonstrated that Prolanta™ has a novel mechanism of action, induced autophagy) against ovarian cancer, and also demonstrated the synergy of Prolanta™ with other chemotherapy drugs. See Ovarian Cancer and Prolanta™.
Breast Cancer. Our founding scientist, Wen Chen, PhD, developed substantial evidence of the efficacy of Prolanta™ in breast cancer models. See Breast Cancer and Prolanta™.
Other Cancers. Human prolactin is associated with many other cancers, and we believe there are commercial opportunities for Prolanta™ in these cancers. See Other Cancers.